Epidermal growth factor receptor-inhibitors and radiotherapy-induced cutaneous adverse effects: "Koebner-Phenomenon" or radio-dermatitis?

Radiotherapy and Oncology

Volumn 92, Issue 1, 2009, Pages 142-143

  Merlano, Marco C ^a   Russi, Elvio G ^b  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b Ospedale Cardinal Massaia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

CANCER RADIOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DISABILITY SEVERITY; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYDROCOLLOID; LETTER; PATHOGENESIS; PRIORITY JOURNAL; RADIATION DERMATITIS; SKIN TOXICITY;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIODERMATITIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 66949172037     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.03.001     Document Type: Letter

References (17)

1. Eriksen J.G., and Overgaard M. Late onset of skin toxicity induced by EGFr-inhibitors. Radiother Oncol 90 (2009) 280-281
2. Giro C., Berger B., Bölke E., et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC Institutes. Radiother Oncol 90 (2009) 166-171
3. Pryor D.I., Porceddu S.V., Burmeister B.H., et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90 (2009) 172-176
4. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
5. Merlano MC, Benasso M, Numico G. et al. Chemo-radiation (ctrt) and cetuximab (cmab) in locally advanced head and neck cancer (LA HNC). 33° ESMO meeting, Stockholm 2008. Ann Oncol 2008;19(Suppl. 8) [abstr. 694PD].
6. Russi E.G., Merlano M.C., Comino A., and Numico G. Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. altercc Italian trial). Int J Radiation Oncology Biol Phys 69 (2007) 638-641 [letter]
7. Mydin A.R., and Armstrong J.G. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol 85 (2007) 171
8. Budach W., Bölke E., and Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357 (2007) 514-515
9. Common Terminology Criteria for Adverse Events v3.0 (CTCAE); 2006. p. 15. Available from:
10. Bölke E., Gerber P.A., Lammering G., et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184 (2008) 105-110
11. Peter R.U., Beetz A., Ried C., et al. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res 136 (1993) 65-70
12. Madison K.C. Barrier function of the skin: ''La Raison d'EOEtre'' of the epidermis: a review. J Invest Dermatol 121 (2003) 231-241
13. Woodworth C.D., Michael E., Marker D., et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 4 (2005) 650-658
14. Mascia F., Mariani V., Girolomoni G., et al. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 163 (2003) 303-312
15. Pastore S., Mascia F., Mariotti F., et al. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 174 (2005) 5047-5056
16. Gerber P.A., Enderlein E., and Homey B. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. JCO (2008) 2790-2792
17. Weiss G., Shemer A., and Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol 16 (2002) 241-248